What is Kazia Therapeutics Ltd ADR?
Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical teratoid rhabdoid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 76.50M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.